Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 251 participants.
Also called NCT03470545
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 251 participants
- Sponsor
- MyoKardia, Inc.
- Registry
-
NCT03470545
-
- Other papers using this trial's data
- Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial
- Association Between age or Duration of Diagnosis in Obstructive Hypertrophic Cardiomyopathy and Response to Mavacamten Treatment: Exploratory Analysis of the EXPLORER-HCM Trial
- Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy
- Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption: A Secondary Analysis of the EXPLORER-HCM Randomized Trial
- Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
- Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
- The Kansas City Cardiomyopathy Questionnaire in Relation to New York Heart Association Class
- The Psychometric Performance of the Kansas City Cardiomyopathy Questionnaire-12 in Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Belgium, Czechia, Denmark, France, Germany, Israel, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03470545. Randomized; quadruple masking; primary purpose treatment. Start 2018-05-29 (actual); primary completion 2020-03-14 (actual). Results posted on 2021-10-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Acronym
- EXPLORER-HCM
- Condition
- Obstructive Hypertrophic Cardiomyopathy
- Intervention (Drug)
- mavacamten
- Intervention (Drug)
- Placebo
- Lead sponsor
- MyoKardia, Inc.
Record details
- Record id
cardio:ct-nct03470545- Content hash
846e2466d7b01ced40d93a20436201a13d7f43868dc8c9243c0339cb11bd9a00